[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "",
    "text": "Study Objective: Examine racial disparities in patients with cancer and heart failure.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a diagnosis of cancer and heart failure.\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, tobacco and alcohol use disorder.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "",
    "text": "Study Objective: Examine racial disparities in patients with cancer and heart failure.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a diagnosis of cancer and heart failure.\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, tobacco and alcohol use disorder.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 842,8501\nWhite N = 628,0901\nAsian or Pacific Islander N = 16,9701\nBlack N = 126,6601\nHispanic N = 50,2401\nNative American N = 3,3451\nOther N = 17,5451\np-value2\n\n\n\n\nAge, y\n76 (67, 83)\n77 (69, 84)\n76 (68, 83)\n70 (62, 78)\n73 (64, 82)\n71 (63, 79)\n74 (66, 82)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n357,175 (42%)\n258,035 (41%)\n7,105 (42%)\n61,390 (48%)\n21,630 (43%)\n1,630 (49%)\n7,385 (42%)\n\n\n\n\n    Male\n485,665 (58%)\n370,055 (59%)\n9,865 (58%)\n65,265 (52%)\n28,610 (57%)\n1,715 (51%)\n10,155 (58%)\n\n\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n235,135 (28%)\n143,270 (23%)\n1,830 (11%)\n65,800 (53%)\n18,295 (37%)\n1,445 (46%)\n4,495 (26%)\n\n\n\n\n    $52,000 - $65,999\n218,600 (26%)\n171,710 (28%)\n3,035 (18%)\n26,525 (21%)\n12,640 (26%)\n885 (28%)\n3,805 (22%)\n\n\n\n\n    $66,000 - $87,999\n202,310 (24%)\n161,585 (26%)\n4,750 (28%)\n20,045 (16%)\n11,260 (23%)\n555 (18%)\n4,115 (24%)\n\n\n\n\n    $88,000 or more\n174,440 (21%)\n142,720 (23%)\n7,200 (43%)\n12,445 (10.0%)\n7,110 (14%)\n275 (8.7%)\n4,690 (27%)\n\n\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n45,940 (5.5%)\n21,160 (3.4%)\n1,710 (10%)\n14,315 (11%)\n6,465 (13%)\n450 (14%)\n1,840 (11%)\n\n\n\n\n    Medicare\n675,180 (80%)\n520,420 (83%)\n12,440 (73%)\n91,195 (72%)\n35,850 (71%)\n2,400 (72%)\n12,875 (73%)\n\n\n\n\n    No charge\n695 (&lt;0.1%)\n390 (&lt;0.1%)\n20 (0.1%)\n170 (0.1%)\n85 (0.2%)\n5 (0.2%)\n25 (0.1%)\n\n\n\n\n    Other\n17,455 (2.1%)\n13,170 (2.1%)\n220 (1.3%)\n2,610 (2.1%)\n890 (1.8%)\n180 (5.4%)\n385 (2.2%)\n\n\n\n\n    Private\n94,600 (11%)\n67,950 (11%)\n2,405 (14%)\n16,210 (13%)\n5,665 (11%)\n280 (8.4%)\n2,090 (12%)\n\n\n\n\n    Self-pay\n8,200 (1.0%)\n4,455 (0.7%)\n170 (1.0%)\n1,995 (1.6%)\n1,265 (2.5%)\n10 (0.3%)\n305 (1.7%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n210,225 (25%)\n173,515 (28%)\n1,620 (9.5%)\n28,785 (23%)\n3,665 (7.3%)\n795 (24%)\n1,845 (11%)\n\n\n\n\n    Northeast\n172,580 (20%)\n133,360 (21%)\n2,710 (16%)\n21,315 (17%)\n9,435 (19%)\n230 (6.9%)\n5,530 (32%)\n\n\n\n\n    South\n316,220 (38%)\n220,880 (35%)\n2,460 (14%)\n65,610 (52%)\n19,850 (40%)\n1,195 (36%)\n6,225 (35%)\n\n\n\n\n    West\n143,825 (17%)\n100,335 (16%)\n10,180 (60%)\n10,950 (8.6%)\n17,290 (34%)\n1,125 (34%)\n3,945 (22%)\n\n\n\n\nCancer type\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Thyroid\n3,200 (0.4%)\n2,150 (0.3%)\n130 (0.8%)\n430 (0.3%)\n355 (0.7%)\n35 (1.0%)\n100 (0.6%)\n\n\n\n\n    Bone and articular cartilage\n2,095 (0.2%)\n1,540 (0.2%)\n55 (0.3%)\n285 (0.2%)\n165 (0.3%)\n10 (0.3%)\n40 (0.2%)\n\n\n\n\n    Breast\n44,465 (5.3%)\n30,450 (4.9%)\n865 (5.1%)\n9,400 (7.4%)\n2,650 (5.3%)\n240 (7.2%)\n860 (4.9%)\n\n\n\n\n    Central nervous system\n7,170 (0.9%)\n5,445 (0.9%)\n175 (1.0%)\n875 (0.7%)\n460 (0.9%)\n15 (0.4%)\n200 (1.1%)\n\n\n\n\n    Gastrointestinal tract\n127,715 (15%)\n92,490 (15%)\n3,505 (21%)\n18,455 (15%)\n9,830 (20%)\n720 (22%)\n2,715 (16%)\n\n\n\n\n    Genital organs\n85,760 (10%)\n59,955 (9.6%)\n1,645 (9.7%)\n16,770 (13%)\n5,560 (11%)\n205 (6.1%)\n1,625 (9.3%)\n\n\n\n\n    Head and neck\n19,820 (2.4%)\n14,935 (2.4%)\n290 (1.7%)\n3,055 (2.4%)\n1,010 (2.0%)\n75 (2.2%)\n455 (2.6%)\n\n\n\n\n    Hodgkin Lymphoma\n8,160 (1.0%)\n5,945 (1.0%)\n130 (0.8%)\n1,210 (1.0%)\n600 (1.2%)\n20 (0.6%)\n255 (1.5%)\n\n\n\n\n    Leukemia\n141,400 (17%)\n112,815 (18%)\n2,510 (15%)\n14,820 (12%)\n7,470 (15%)\n355 (11%)\n3,430 (20%)\n\n\n\n\n    Lung\n136,845 (16%)\n107,785 (17%)\n2,180 (13%)\n18,850 (15%)\n5,220 (10%)\n595 (18%)\n2,215 (13%)\n\n\n\n\n    Melanoma\n5,000 (0.6%)\n4,615 (0.7%)\n30 (0.2%)\n115 (&lt;0.1%)\n195 (0.4%)\n20 (0.6%)\n25 (0.1%)\n\n\n\n\n    Mesothelium and soft tissue\n12,655 (1.5%)\n8,770 (1.4%)\n300 (1.8%)\n2,380 (1.9%)\n855 (1.7%)\n45 (1.3%)\n305 (1.7%)\n\n\n\n\n    Multiple Myeloma\n83,895 (10.0%)\n52,165 (8.3%)\n1,675 (9.9%)\n22,145 (18%)\n5,770 (12%)\n320 (9.6%)\n1,820 (10%)\n\n\n\n\n    Neuroendocrine\n290 (&lt;0.1%)\n230 (&lt;0.1%)\n0 (0%)\n35 (&lt;0.1%)\n10 (&lt;0.1%)\n0 (0%)\n15 (&lt;0.1%)\n\n\n\n\n    Non-Hodgkin Lymphoma\n88,900 (11%)\n69,980 (11%)\n2,120 (13%)\n8,675 (6.9%)\n5,830 (12%)\n350 (10%)\n1,945 (11%)\n\n\n\n\n    Others\n7,550 (0.9%)\n5,895 (0.9%)\n180 (1.1%)\n900 (0.7%)\n370 (0.7%)\n30 (0.9%)\n175 (1.0%)\n\n\n\n\n    Renal\n64,785 (7.7%)\n50,550 (8.1%)\n1,115 (6.6%)\n7,890 (6.2%)\n3,650 (7.3%)\n300 (9.0%)\n1,280 (7.3%)\n\n\n\n\nCharlson comorbidity index\n5.00 (4.00, 7.00)\n5.00 (4.00, 7.00)\n6.00 (4.00, 7.00)\n6.00 (5.00, 7.00)\n6.00 (4.00, 7.00)\n6.00 (4.00, 7.00)\n5.00 (4.00, 7.00)\n&lt;0.001\n\n\nHypertension\n731,540 (87%)\n538,420 (86%)\n14,600 (86%)\n116,635 (92%)\n44,265 (88%)\n2,720 (81%)\n14,900 (85%)\n&lt;0.001\n\n\nDiabetes mellitus\n347,760 (41%)\n241,190 (38%)\n8,775 (52%)\n61,185 (48%)\n27,210 (54%)\n1,620 (48%)\n7,780 (44%)\n&lt;0.001\n\n\nChronic kidney disease\n366,160 (43%)\n259,085 (41%)\n8,500 (50%)\n66,805 (53%)\n23,135 (46%)\n1,415 (42%)\n7,220 (41%)\n&lt;0.001\n\n\nLiver disease\n67,845 (8.0%)\n45,075 (7.2%)\n2,125 (13%)\n11,170 (8.8%)\n7,195 (14%)\n455 (14%)\n1,825 (10%)\n&lt;0.001\n\n\nCOPD\n344,995 (41%)\n267,035 (43%)\n4,760 (28%)\n49,965 (39%)\n15,695 (31%)\n1,485 (44%)\n6,055 (35%)\n&lt;0.001\n\n\nPeripheral vascular disease\n136,590 (16%)\n103,910 (17%)\n2,695 (16%)\n19,590 (15%)\n7,605 (15%)\n340 (10%)\n2,450 (14%)\n&lt;0.001\n\n\nAtrial fibrillation\n317,755 (38%)\n258,465 (41%)\n5,590 (33%)\n32,130 (25%)\n14,945 (30%)\n1,020 (30%)\n5,605 (32%)\n&lt;0.001\n\n\nCerebrovascular disease\n61,770 (7.3%)\n43,640 (6.9%)\n1,415 (8.3%)\n11,425 (9.0%)\n3,690 (7.3%)\n195 (5.8%)\n1,405 (8.0%)\n&lt;0.001\n\n\nHyperlipidemia\n435,160 (52%)\n331,140 (53%)\n9,085 (54%)\n59,655 (47%)\n25,120 (50%)\n1,475 (44%)\n8,685 (50%)\n&lt;0.001\n\n\nCoronary artery disease\n372,555 (44%)\n290,495 (46%)\n6,890 (41%)\n45,930 (36%)\n20,215 (40%)\n1,440 (43%)\n7,585 (43%)\n&lt;0.001\n\n\nTobbacco use disorder\n4,340 (0.5%)\n3,095 (0.5%)\n40 (0.2%)\n820 (0.6%)\n225 (0.4%)\n40 (1.2%)\n120 (0.7%)\n0.001\n\n\nAlcohol use disorder\n246,765 (29%)\n181,785 (29%)\n4,770 (28%)\n39,300 (31%)\n15,065 (30%)\n1,235 (37%)\n4,610 (26%)\n0.014\n\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nWhite N = 628,0901\nAsian or Pacific Islander N = 16,9701\nBlack N = 126,6601\nHispanic N = 50,2401\nNative American N = 3,3451\nOther N = 17,5451\np-value2\n\n\n\n\nDied during hospitalization\n46,355 (7.4%)\n1,630 (9.6%)\n8,465 (6.7%)\n3,935 (7.8%)\n320 (9.6%)\n1,560 (8.9%)\n&lt;0.001\n\n\nLength of stay (days)\n5 (3, 9)\n5 (3, 9)\n5 (3, 9)\n5 (3, 9)\n5 (3, 8)\n6 (3, 10)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n49,660 (26,500, 97,908)\n70,571 (39,140, 141,009)\n51,735 (27,638, 102,034)\n71,583 (38,151, 141,861)\n43,797 (24,454, 84,694)\n68,111 (34,785, 142,815)\n&lt;0.001\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nRACE\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.24\n1.10, 1.41\n&lt;0.001\n\n\n    Black\n1.01\n0.95, 1.08\n0.7\n\n\n    Hispanic\n1.05\n0.97, 1.14\n0.2\n\n\n    Native American\n1.28\n0.98, 1.66\n0.069\n\n\n    Other\n1.20\n1.06, 1.36\n0.004\n\n\nAge, y\n1.02\n1.02, 1.02\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.15\n1.10, 1.20\n&lt;0.001\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.94\n0.89, 0.99\n0.029\n\n\n    $66,000 - $87,999\n0.95\n0.90, 1.01\n0.10\n\n\n    $88,000 or more\n0.95\n0.89, 1.00\n0.071\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n0.96\n0.87, 1.06\n0.4\n\n\n    No charge\n1.05\n0.49, 2.26\n0.9\n\n\n    Other\n2.06\n1.78, 2.38\n&lt;0.001\n\n\n    Private\n1.42\n1.28, 1.58\n&lt;0.001\n\n\n    Self-pay\n1.40\n1.14, 1.71\n0.001\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.22\n1.14, 1.30\n&lt;0.001\n\n\n    South\n1.03\n0.98, 1.09\n0.3\n\n\n    West\n1.16\n1.09, 1.24\n&lt;0.001\n\n\nCancer type\n\n\n\n\n\n\n\n\n    Thyroid\n—\n—\n\n\n\n\n    Bone and articular cartilage\n1.57\n0.93, 2.66\n0.090\n\n\n    Breast\n0.91\n0.61, 1.35\n0.6\n\n\n    Central nervous system\n1.64\n1.08, 2.51\n0.022\n\n\n    Gastrointestinal tract\n1.35\n0.92, 1.98\n0.13\n\n\n    Genital organs\n0.95\n0.64, 1.40\n0.8\n\n\n    Head and neck\n1.37\n0.91, 2.05\n0.13\n\n\n    Hodgkin Lymphoma\n1.98\n1.31, 3.00\n0.001\n\n\n    Leukemia\n1.75\n1.20, 2.57\n0.004\n\n\n    Lung\n2.03\n1.38, 2.97\n&lt;0.001\n\n\n    Melanoma\n1.09\n0.68, 1.74\n0.7\n\n\n    Mesothelium and soft tissue\n1.47\n0.98, 2.21\n0.065\n\n\n    Multiple Myeloma\n1.40\n0.95, 2.05\n0.089\n\n\n    Neuroendocrine\n1.24\n0.41, 3.74\n0.7\n\n\n    Non-Hodgkin Lymphoma\n1.61\n1.09, 2.36\n0.015\n\n\n    Others\n1.36\n0.88, 2.10\n0.2\n\n\n    Renal\n0.98\n0.67, 1.45\n&gt;0.9\n\n\nCharlson comorbidity index\n1.03\n1.01, 1.06\n0.010\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.68\n0.64, 0.71\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.87\n0.82, 0.92\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.02\n0.95, 1.09\n0.6\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.64\n0.62, 0.67\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.81\n0.77, 0.84\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.20\n2.05, 2.36\n&lt;0.001\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.92\n0.88, 0.97\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.86\n0.81, 0.91\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.10\n1.06, 1.15\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.51\n1.41, 1.62\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.66\n0.48, 0.92\n0.015\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.09\n1.04, 1.14\n&lt;0.001\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Racial Disparities in the Management and Outcomes of Cancer and Comorbid Heart Failure",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nRACE\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.2\n0.72, 1.6\n&lt;0.001\n\n\n    Black\n0.41\n0.27, 0.56\n&lt;0.001\n\n\n    Hispanic\n0.45\n0.23, 0.67\n&lt;0.001\n\n\n    Native American\n-0.45\n-1.0, 0.13\n0.13\n\n\n    Other\n1.2\n0.79, 1.6\n&lt;0.001\n\n\nAge, y\n-0.06\n-0.06, -0.05\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.03\n-0.06, 0.12\n0.5\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-0.05\n-0.16, 0.06\n0.4\n\n\n    $66,000 - $87,999\n0.12\n0.00, 0.25\n0.051\n\n\n    $88,000 or more\n0.28\n0.13, 0.42\n&lt;0.001\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-0.29\n-0.59, 0.00\n0.052\n\n\n    No charge\n0.62\n-1.2, 2.5\n0.5\n\n\n    Other\n-0.53\n-1.0, -0.04\n0.032\n\n\n    Private\n0.08\n-0.26, 0.41\n0.7\n\n\n    Self-pay\n-0.73\n-1.3, -0.18\n0.010\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.79\n0.61, 0.97\n&lt;0.001\n\n\n    South\n0.40\n0.26, 0.54\n&lt;0.001\n\n\n    West\n-0.05\n-0.24, 0.14\n0.6\n\n\nCancer type\n\n\n\n\n\n\n\n\n    Thyroid\n—\n—\n\n\n\n\n    Bone and articular cartilage\n1.7\n0.61, 2.7\n0.002\n\n\n    Breast\n-0.46\n-1.2, 0.28\n0.2\n\n\n    Central nervous system\n1.7\n0.84, 2.6\n&lt;0.001\n\n\n    Gastrointestinal tract\n1.4\n0.62, 2.1\n&lt;0.001\n\n\n    Genital organs\n-0.05\n-0.78, 0.68\n0.9\n\n\n    Head and neck\n2.5\n1.7, 3.3\n&lt;0.001\n\n\n    Hodgkin Lymphoma\n0.78\n-0.11, 1.7\n0.085\n\n\n    Leukemia\n1.4\n0.69, 2.2\n&lt;0.001\n\n\n    Lung\n0.35\n-0.38, 1.1\n0.3\n\n\n    Melanoma\n-0.05\n-0.87, 0.77\n0.9\n\n\n    Mesothelium and soft tissue\n0.73\n-0.07, 1.5\n0.072\n\n\n    Multiple Myeloma\n0.64\n-0.10, 1.4\n0.090\n\n\n    Neuroendocrine\n2.8\n-0.15, 5.8\n0.063\n\n\n    Non-Hodgkin Lymphoma\n1.1\n0.32, 1.8\n0.005\n\n\n    Others\n0.66\n-0.17, 1.5\n0.12\n\n\n    Renal\n0.40\n-0.34, 1.1\n0.3\n\n\nCharlson comorbidity index\n0.34\n0.27, 0.40\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.54\n-0.70, -0.38\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.68\n-0.82, -0.54\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.52\n-0.70, -0.35\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.92\n-1.0, -0.83\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.82\n-0.90, -0.74\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.19\n0.00, 0.39\n0.054\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.56\n-0.67, -0.46\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.70\n-0.82, -0.58\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.32\n0.24, 0.41\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.3\n1.1, 1.6\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.2\n-1.6, -0.83\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.07\n-0.07, 0.21\n0.3\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nRACE\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n25,242\n15,548, 34,935\n&lt;0.001\n\n\n    Black\n3,185\n293, 6,077\n0.031\n\n\n    Hispanic\n26,733\n21,337, 32,130\n&lt;0.001\n\n\n    Native American\n-23,899\n-32,466, -15,332\n&lt;0.001\n\n\n    Other\n31,612\n22,941, 40,283\n&lt;0.001\n\n\nAge, y\n-1,676\n-1,838, -1,514\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n5,238\n3,515, 6,962\n&lt;0.001\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1,327\n-849, 3,502\n0.2\n\n\n    $66,000 - $87,999\n5,759\n3,307, 8,212\n&lt;0.001\n\n\n    $88,000 or more\n15,419\n11,836, 19,003\n&lt;0.001\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n9,510\n4,033, 14,987\n&lt;0.001\n\n\n    No charge\n450\n-23,730, 24,630\n&gt;0.9\n\n\n    Other\n4,423\n-4,191, 13,036\n0.3\n\n\n    Private\n18,636\n11,783, 25,489\n&lt;0.001\n\n\n    Self-pay\n-13,517\n-21,604, -5,429\n0.001\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n23,805\n18,536, 29,075\n&lt;0.001\n\n\n    South\n14,063\n10,846, 17,279\n&lt;0.001\n\n\n    West\n49,220\n41,420, 57,020\n&lt;0.001\n\n\nCancer type\n\n\n\n\n\n\n\n\n    Thyroid\n—\n—\n\n\n\n\n    Bone and articular cartilage\n23,127\n736, 45,517\n0.043\n\n\n    Breast\n-16,984\n-28,896, -5,073\n0.005\n\n\n    Central nervous system\n9,967\n-3,622, 23,556\n0.2\n\n\n    Gastrointestinal tract\n7,602\n-4,441, 19,646\n0.2\n\n\n    Genital organs\n-9,658\n-21,608, 2,293\n0.11\n\n\n    Head and neck\n32,241\n18,095, 46,388\n&lt;0.001\n\n\n    Hodgkin Lymphoma\n2,820\n-11,818, 17,457\n0.7\n\n\n    Leukemia\n11,857\n-460, 24,174\n0.059\n\n\n    Lung\n-6,971\n-18,951, 5,009\n0.3\n\n\n    Melanoma\n-9,254\n-22,761, 4,252\n0.2\n\n\n    Mesothelium and soft tissue\n754\n-12,832, 14,340\n&gt;0.9\n\n\n    Multiple Myeloma\n-5,776\n-17,873, 6,322\n0.3\n\n\n    Neuroendocrine\n42,055\n-30,573, 114,683\n0.3\n\n\n    Non-Hodgkin Lymphoma\n8,210\n-3,876, 20,296\n0.2\n\n\n    Others\n1,442\n-12,598, 15,483\n0.8\n\n\n    Renal\n-1,960\n-13,949, 10,028\n0.7\n\n\nCharlson comorbidity index\n2,545\n1,401, 3,689\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-9,792\n-13,090, -6,494\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-9,559\n-11,987, -7,131\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-7,653\n-10,734, -4,573\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-9,144\n-10,738, -7,550\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-4,368\n-5,859, -2,876\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n15,033\n10,629, 19,437\n&lt;0.001\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-9,377\n-11,412, -7,341\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-6,584\n-8,795, -4,373\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2,801\n1,239, 4,362\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n26,062\n22,236, 29,887\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-15,982\n-23,145, -8,819\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n6,314\n1,924, 10,704\n0.005\n\n\n\n1 CI = Confidence Interval"
  }
]